CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 500 enrolled
Drug / intervention
Eravacycline +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02784704
NCT02784704Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Tetraphase Pharmaceuticals, Inc·interventional·Posted May 27, 2016·Updated Jan 6, 2022

In Brief

A Phase 3 clinical trial evaluating Eravacycline, Meropenem, and 1 other intervention for Complicated Intra-abdominal Infections and Complicated Appendicitis. Completed, enrolled 500 participants across 54 sites in 11 countries.

Detailed Summary

This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics (PK) of eravacycline compared with meropenem in the treatment of complicated intra-abdominal infections (cIAIs).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsComplicated Intra-abdominal Infections, Complicated Appendicitis
CountriesBulgaria, Czechia, Estonia, Georgia, Hungary, Latvia, Lithuania, Romania, Russia, Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 27, 2016
Enrollment StartOct 13, 2016
Primary CompletionMay 8, 2017
Study CompletionMay 19, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.1 years ago

Interventions

Eravacyclinedrug

Meropenemdrug

Placebodrug